Shilpa Gupta, MD

Where You Are:
Shilpa Gupta, MD

Assistant Member

Office  (813) 745-3973

Education And Training
  • Research Fellow, Thomas Jefferson University, 2011 - Genitourinary Oncology
  • Fellow, Thomas Jefferson University, 2010 - Hematology Oncology
  • Fellow, Medical College of Wisconsin, 2009 - Hematology Oncology
  • Fellow, Georgetown University, 2008 - Hematology Oncology
  • Resident, University of Connecticut, 2007 - Internal Medicine
  • Intern, University of Connecticut, 2005 - Internal Medicine
  • Fellow, Royal College of General Practitioners, UK, 2002 - Emergency Medicine
  • MBBS, Lady Hardinge Medical College, New Delhi, India, 2001

My research interests include developing novel therapeutics for treatment of genitourinary malignancies.  My translational research has been focused on testing small-molecule inhibitors targeting the Jak2/Stat5a/b signaling pathway in prostate cancer using ex-vivo preclinical model systems like human prostate cancer organ cultures. 

Our laboratory has shown that active Stat5a/b is critical for prostate cancer cell survival and growth and that the Jak2/Stat5a/b signaling pathway in prostate cancer plays a role in the progression of organ-confined prostate cancer to castration-resistant and/or disseminated disease.  The Jak2/Stat5a/b pathway provides various molecular targets for developing rational targeted therapeutics for prostate cancer and we have tested small-molecule inhibitors including Jak2 inhibitor and Stat5 inhibitor targeting this pathway with promising results.

I am interested in developing early phase clinical trials using novel targeted agents for genitourinary cancers with an emphasis on prostate and bladder cancer.

  • Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun;13(3):225-230. Pubmedid: 25544725.
  • Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May;33(14):1601-1608. Pubmedid: 25847934. Pmcid: PMC4417730.
  • Gupta S, Gill D, Pal SK, Agarwal N. Activin receptor inhibitors-dalantercept. Curr Oncol Rep. 2015 Apr;17(4):441. Pubmedid: 25708802.
  • Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. J Natl Compr Canc Ne. 2015 Feb;13(2):151-159. Pubmedid: 25691606.
  • Hoang DT, Gu L, Liao Z, Shen F, Talati P, Koptyra M, Tan S, Ellsworth E, Gupta S, Montie H, Dagvadorj A, Savolainen S, Leiby B, Mirtti T, Merry D, Nevalainen MT. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. Mol Cancer Ther. 2014 Dec. Pubmedid: 25552366.
  • Gallaher J, Cook LM, Gupta S, Araujo A, Dhillon J, Park JY, Scott JG, Pow-Sang J, Basanta D, Lynch CC. Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin Exp Metastas. 2014 Dec;31(8):991-999. Pubmedid: 25173680.
  • Agarwal G, Gupta S, Spiess PE. Novel targeted therapies for the treatment of penile cancer. Expert Opin Drug Discov. 2014 Aug;9(8):959-968. Pubmedid: 24896220.
  • Dolan DE, Gupta S. PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy. Cancer Control. 2014 Jul;21(3):231-237. Pubmedid: 24955707.
  • Freilich JM, Spiess PE, Biagioli MC, Fernandez DC, Shi EJ, Hunt DC, Gupta S, Wilder RB. Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer. Int Braz J Urol. 2014 May;40(2):190-197. Pubmedid: 24856485.
  • Baumgarten AS, Emtage JB, Wilder RB, Biagioli MC, Gupta S, Spiess PE. Intravesical lipiodol injection technique for image-guided radiation therapy for bladder cancer. Urology. 2014 Apr;83(4):946-950. Pubmedid: 24397940.
  • Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R. Kidney cancer, version 2.2014. J Natl Compr Canc Ne. 2014 Feb;12(2):175-182. Pubmedid: 24586079.
  • Mahipal A, Kothari N, Gupta S. Epidermal growth factor receptor inhibitors: coming of age. Cancer Control. 2014 Jan;21(1):74-79. Pubmedid: 24357745.
  • Nevalainen MT, Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, Ellsworth E, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue PA, Gomella LG, Huszar D. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin Cancer Res. 2013 Oct;19(20):5658-5674. Pubmedid: 23942095.
  • Gupta S, Spiess PE. The prospects of pazopanib in advanced renal cell carcinoma. Ther Adv Urol. 2013 Oct;5(5):223-232. Pubmedid: 24082917. Pmcid: PMC3763778.
  • Gupta S, Mahipal A. Role of systemic chemotherapy in urothelial urinary bladder cancer. Cancer Control. 2013 Jul;20(3):200-210. Pubmedid: 23811704.
  • Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular cancer. J Natl Compr Canc Netw. 2012 Apr;10(4):502-535. Pubmedid: 22491049.
  • Gupta S, Fishman M. Progress and contrasts of the development of tivozanib for therapy of kidney cancer. Expert Opin Pharmacother. 2011 Dec;12(18):2915-2922. Pubmedid: 22098229.
  • Gupta S, Gupta R, Singh S, Pant L. Solitary intrascrotal neurofibroma: A case diagnosed on aspiration cytology. Diagn Cytopathol. 2011 Nov;39(11):843-846. Pubmedid: 21994196.
  • Gupta S, Carballido E, Fishman M. Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. Onco Targets Ther. 2011 Nov;4:79-96. Pubmedid: 21792315. Pmcid: PMC3143908.
  • Koptyra M, Gupta S, Talati P, Nevalainen MT. Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer. Int J Biochem Cell B. 2011 Oct;43(10):1417-1421. Pubmedid: 21704724. Pmcid: PMC3163765.
  • Mahipal A, Gupta S. Small-cell carcinoma of the gallbladder: report of a case and literature review. Gastrointest Cancer Res. 2011 Jul;4(4):135-136. Pubmedid: 22368737. Pmcid: PMC3283103.
  • Dua V, Gupta S, Singh C. Evaluation of the nasolabial angle in the Indian population. Contemp Clin Dent. 2010 Apr;1(2):79-82. Pubmedid: 22114388. Pmcid: PMC3220091.
  • Gupta S, Mahipal A. A case of acquired hemophilia associated with bullous pemphigoid. Am J Hematol. 2007 Jun;82(6):502. Pubmedid: 17301969.
  • Gupta S, Mahipal A. Fatal pulmonary toxicity after a single dose of cyclophosphamide. Pharmacotherapy. 2007 Apr;27(4):616-618. Pubmedid: 17381391.
  • Weinberg B, Gupta S, Thomas MJ, Stern H. Pott's puffy tumor: Sonographic diagnosis. J Clin Ultrasound. 2005;33(6):305-307. Pubmedid: 16134159.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions